Real-Time Liquid Biopsy Cancer Diagnosis and Monitoring
- 技術應用
- Early detection and real-time monitoring ofcancer DNA from non-invasive liquid biopsy samplesTumor tissue-of-origin determinationCancer sub-type classificationKey applications will be in oncology, forensics, genetic profiling, andenvironmental testing
- 詳細技術說明
- Non-invasive liquid biopsy to diagnose specific cancer subtypesusing genome-wide DNA methylation and transcription factor profiles
- *Abstract
-
DNA methylation profiles are highly cell-typespecific and are disrupted in many diseases, including cancer. Here weintroduce Cell-Free Methylated DNA Immunoprecipitation and High-throughputSequencing (cfMeDIP-seq), a robust picogram - nanogram input method suitablefor genome-wide methylome analysis of cell-free DNA (cfDNA). Current detectionmethods from solid tumors and liquid samples are impractical due to their insensitiveand non-specific diagnoses. Invasivebiopsies can also lead to tissue damage and increased metastasis. The disclosed technology utilizes cfDNAisolated from cancer patients to subtype cancer and determine the tissue oforigin. Therefore, cfMeDIPseq could beused to detect circulating tumor DNA, to infer tissue-of-origin and classifycancer patients. This technology reducesthe health impact on patients during biopsies and significantly improves thedetection limits 10X over previous liquid biopsies using DNA markers as used inother PCR-based systems. The detection limits are sufficient to be appliedacross multiple indications.
Tumorsare a complex problem that require stringent monitoring (Junttila and deSauvage. Nature). cfMeDIP-seq wasperformed in circulating cfDNA from patient blood samples. For the samepatients, cfMeDIP-seq was also performed in circulating cfDNA from the blood of15 age- and gender-matched healthy donors.
- *Principal Investigation
-
Dr. Daniel De Carvalho, Princess Margaret Cancer Centre,University Health Network
- *Publications
- Clinical Applications of Circulating Tumor Cells andCirculating Tumor DNA as Liquid Biopsy.Alix-Panabières C, et al. 2016 May;6(5):479-91. doi:10.1158/2159-8290.CD-15-1483. Review.Influence of tumour micro-environment heterogeneityon therapeutic response.Junttila and de Sauvage. Nature.2013, 501:346-354
- 國家/地區
- 美國
